Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction
Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction
复制标题
DOI：
10.1097/01.ico.0000176611.88579.0a
复制
发表时间：
2006-02-01
期刊：
影响因子：
2.8
通讯作者：
Bloom, AH
中科院分区：
文献类型：
--
作者：
Perry, HD;Doshi-Carnevale, S;Bloom, AH
目的：探讨外用0.05%环孢素A(TCSA)(Restasiso(R)，Allergan PharmPharmticals)治疗睑板腺功能障碍(后睑炎)的疗效。方法：33例症状性眼睑功能障碍患者随机分为TCSA组和安慰剂组，每日2次，共3个月。在治疗前、治疗后1、2、3个月分别对患者的主观症状和客观体征进行评估，包括眼睑汗腺包涵体、眼睑边缘血管注射、睑板毛细血管扩张、荧光素染色、泪液破裂时间和Schirmer评分。结果：26例患者完成研究。所有患者均接受了眼部症状、眼睑边缘血管密度、睑板毛细血管扩张、眉肌腺包涵体、泪液破裂时间和荧光素染色的检查。在3个月的访问中，TCSA组的眼部症状比安慰剂组有更大的改善，但这种差异在统计学上并不显著。在3个月的访问中，与安慰剂组相比，TCSA组的几项客观检查结果在统计学上有显著改善(P<；0.05)。这些差异包括眼睑边缘血管注射、颧骨毛细血管扩张和荧光素染色。最显著的发现(P=0.001)是TCSA组与安慰剂组相比，眉板腺内含物的减少。结论：局部应用CsA可能有助于治疗眉板腺功能障碍(后睑缘炎)。局部应用环孢素A并不能改善症状，但确实减少了眉板腺功能障碍患者的眉板腺包裹体的数量。
Objective: To investigate the efficacy of topical cyclosporine A 0.05% (tCsA) (Restasiso (R), Allergan Pharmaceuticals) in the treatment of meibomian gland dysfunction (posterior blepharitis).Methods: Thirty-three patients with symptomatic meibomian gland dysfunction were randomized in a prospective study to either tCsA or placebo (Refresh Plus (R) preservative-free artificial tears), 2 times daily for 3 months. They were evaluated at baseline and at 1, 2, and 3 months for subjective symptoms and objective signs including meibomian gland inclusions, lid margin vascular injection, tarsal telangiectasis, fluorescein staining, tear breakup time, and Schirmer scores.Results: Twenty-six patients completed the study. All patients were tested for ocular symptoms, lid margin vascularity, tarsal telangiectasis, meibomian gland inclusions, tear breakup time, and fluorescein staining. At the 3-month visit, the tCsA group showed a greater improvement in ocular symptoms than the placebo group, but this difference was not statistically significant. At the 3-month visit, several objective examination findings were statistically significantly (P < 0.05) improved in the tCsA group compared with the placebo group. These differences included lid margin vascular injection, tarsal telangiectasis, and fluorescein staining. The most significant finding (P = 0.001) was the greater decrease in the number of meibomian gland inclusions in the tCsA group compared with the placebo group.Conclusions: Topical CsA may be helpful in the treatment of meibomian gland dysfunction (postetior blepharitis). Topical CsA did not induce an improvement in the symptoms, but it did decrease the number of meibomian gland inclusions in patients with meibomian gland dysfunction.